shutterstock_1846479097_rafapress
rafapress / Shutterstock.com
21 March 2023Big PharmaLiz Hockley

Exelixis takes Cipla to court over generic cancer drug

Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Big Pharma
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

More on this story

Big Pharma
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Big Pharma
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

More on this story

Big Pharma
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Big Pharma
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.